Corrigendum: Interferon-α2b Treatment for COVID-19.

[This corrects the article DOI: 10.3389/fimmu.2020.01061.].

Error in Figure/Table

In the original article, there was a mistake in as published. For ‘Days from symptom onset to treatment,’ the IFN+ARB and ARB values were inadvertently switched. IFN+ARB should be 8.0 [5.0,11.0] and ARB should be 17.0 [10.0, 22.0]. The corrected appears below.

Table 1

Demographics and clinical characteristics of patient cohort.

	IFN n = 7	IFN+ARB n = 46	ARBn = 24	p-value
Age, yrs	41.3 (27–68)	40.4 (25–80)	64.5 (37–73)	<0.001
Male (%)Female (%)	0 (0.0%)7 (100%)	20 (43.5%)26 (56.5%)	11 (45.8%)13 (54.2%)	0.076
Comorbidities (%) a	14.3%	15.2%	54.2%	0.002
Initial symptoms
Fever (%)	57.1%	58.7%	70.8%	0.632
Cough (%)	42.9%	50.0%	54.2%	0.888
Fatigue (%)	14.3%	23.9%	37.5%	0.422
Myalgia (%)	14.3%	13.0%	29.2%	0.228
Headache (%)	14.3%	6.52%	4.17%	0.590
Pharyngalgia (%)	0.00%	13.0%	8.33%	0.742
Chest pain (%)	14.3%	6.52%	20.8%	0.134
Expectoration (%)	14.3%	8.70%	20.8%	0.281
Nausea (%)	0.00%	0.00%	4.17%	0.403
Diarrhea (%)	14.3%	4.35%	20.8%	0.081
Days from symptom onset to hospital admission b	8.0[5.5, 15.5]	6.5[3.0, 10.0]	10.0[4.5, 19.5]	0.087
Days from symptom onset to 1st treatment b	8.0[6.5, 16.00]	8.0[5.25, 11.0]	17.0[10.0, 22.0]	<0.001

Hypertension, diabetes, COPD, chronic bronchitis, heart disease, cancer.

Median and interquartile range [Q1, Q3] are reported.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.